Aesica to Collaborate with QRxPharma for the Worldwide Promotion of Stealth Beadlets Abuse Deterrence Technology
<p> Aesica Pharmaceuticals, the global contract development and manufacturing organization (CDMO), has announced the signing of an agreement between its subsidiary, Aesica Formulation Development Ltd, and QRxPharma Ltd, for the global promotion of QRxPharma’s proprietary Stealth Beadlets abuse deterrence technology.</p> <p> Aesica supplies pharmaceutical contract development and manufacturing services internationally and operates six manufacturing sites across the UK, Germany and Italy. The company provides controlled drug services across the supply chain, for which abuse or diversion may occur, and is actively building relationships for supplying controlled drug APIs and finished dose products to market.</p> <p> Under the non-exclusive collaboration agreement, Aesica will promote QRxPharma’s Stealth Beadlets technology for specific use in controlled drugs formulations. The company will enter into fee-for-service contracts with customers for the development of the new Abuse Deterrent Formulations (ADF) of specific drugs, and QRxPharma will negotiate license terms directly with the Aesica clients concerned.</p> <p> QRxPharma’s proprietary Stealth Beadlets abuse deterrence technology was developed for the MOXDUO CR (controlled release) formulation for the treatment of chronic pain. This programme is ready for Phase II studies and has already shown that Stealth Beadlets, incorporated into the company’s delayed release technology, provide a potential once to twice-a-day formulation. Work is underway to assure that this ADF technology fully conforms with FDA guidelines for the provision of abuse deterrence statements in product labelling.</p> <p> Stealth Beadlets can be incorporated into almost any potentially abused drug (e.g., opioids, amphetamines, sedatives, etc.) that are sold in solid dosage forms (e.g., tablet, capsule, sachet). They provide significant resistance against the extraction of active ingredients if crushed, solubilized or heated. Moreover, Stealth Beadlets have no effect on the active ingredient release profile and consist entirely of patient-safe, low cost, excipients that have GRAS (Generally Regarded As Safe) status with FDA. Patent applications for the ADF technology are currently under review at the US patent office, and, if granted, will provide for product exclusivity through to 2029.</p> <p> Alan Raymond, Sales and Marketing Director at Aesica Pharmaceuticals commented: “Aesica is very pleased to have secured this contract with QRxPharma. Indeed, we are committed to providing our customers with the most advanced technologies available for best performance and, consequently, the provision of Stealth Beadlets abuse deterrence technology in formulation development is set to be a highly beneficial addition for our customers in the pharmaceutical and life science markets.”</p> <p> He continued: “We look forward to making this innovative technology readily available to customers across our international network.“ </p> <p> Remarking on the collaboration, Dr John Holaday, Managing Director and Chief Executive Officer at QRxPharma, said: “We are delighted to announce our collaboration with Aesica. Their extensive experience in formulation development and contract manufacturing, together with their established client base in the controlled drugs market, creates a wonderful opportunity for our companies to collaborate in the application of our proprietary abuse deterrence technology by third party pharma companies”.</p> <p> He added: “A head-to-head comparison between Stealth Beadlets and a market leading abuse deterrent technology showed that Stealth Beadlets were more than twice as effective in reducing the percentage of oxycodone that could be extracted from a crushed controlled release tablet.”<br /> </p>
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance